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Abstract
Objectives. We assessed comorbidity burden in people with RA at diagnosis and early disease (3 years) and its
association with early mortality and joint destruction. The association between lung disease and mortality in RA is not
well studied; we also explored this relationship.
Methods. From a contemporary UK-based population (n= 1, 475 762) we identified a cohort with incident RA (n= 6591).
The prevalence of comorbidities at diagnosis of RA and at 3 years was compared with age- and gender-matched controls
(n= 6591). In individuals with RA we assessed the prognostic value of the Charlson Comorbidity Index and Rheumatic
Disease Comorbidity Index calculated at diagnosis for all-cause mortality and joint destruction (with joint surgery as a
surrogate marker). We separately evaluated the association between individual lung diseases [chronic obstructive pul-
monary disease (COPD), asthma and interstitial lung disease] and mortality.
Results. Respiratory disease, cardiovascular disease, stroke, diabetes, previous fracture and depression were more
common (P < 0.05) in patients with RA at diagnosis than controls. Comorbidity (assessed using RDCI) was associated
with all-cause mortality in RA [adjusted hazard ratio (HR) 1.26, 95% CI 1.001.60]. There was no association with joint
destruction. COPD, but not asthma, was associated with mortality (COPD HR 2.84, 95% CI 1.137.12).
Conclusion. There is an excess burden of comorbidity at diagnosis of RA including COPD, asthma and interstitial lung
disease. COPD is a major predictor of early mortality in early RA. Early assessment of comorbidity including lung disease
should form part of the routine management of RA patients.
Key words: rheumatoid arthritis, mortality, joint damage, comorbidity, chronic obstructive pulmonary disease,
asthma, cardiovascular diseases
Rheumatology key messages
. Comorbidities, including respiratory and cardiovascular disease, are disproportionately common in patients with
newly diagnosed RA.
. Individuals with RA accumulate comorbidities more rapidly than controls in the 3 years after diagnosis.
. Chronic obstructive pulmonary disease is a major predictor of mortality in early rheumatoid arthritis.
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Introduction
The long-term prognosis of RA in terms of both function
and mortality has improved with the availability of dis-
ease-modifying antirheumatic drugs (DMARDs) [1, 2],
and a ‘treat to target’ approach accompanied by im-
proved monitoring [3]. Mortality in people with RA remains
higher than in the general population, with cross-sectional
data from the UK suggesting that deaths from cancer,
respiratory and cardiovascular causes are all increased
[4, 5]. In the Early RA Study that recruited consecutive
patients diagnosed with RA from nine centres in
England, a modest increase in mortality was observed
mainly in the first 7 years following diagnosis, although
this was before the widespread introduction of biologic
treatments [6]. Cause of death was similar to the general
population with the exception of increases in infections,
non-Hodgkin’s lymphoma, pulmonary fibrosis and cardio-
vascular-related deaths. While the association between
RA and cardiovascular events has been studied exten-
sively [7], there is a relative paucity of good quality epi-
demiological evidence quantifying the contribution of
respiratory conditions on the outcomes of people with RA.
This study had two main objectives: firstly, to describe
the burden of important comorbidities at diagnosis of RA
compared with people without RA, and then after 3 years
duration of RA, in a contemporary primary care-based
population; and secondly, to evaluate the association of
comorbidity using the Charlson Comorbidity Index (CCI)
and Rheumatic Disease Comorbidity Index (RDCI) at diag-
nosis with all-cause mortality and disease progression in
people with RA [8, 9], as well as the association of indi-
vidual chronic lung conditions with the same outcomes.
Comorbidity indices are tools used to quantify the total
burden of comorbidity based on specific conditions and
have clinical applications in identifying patients with worse
prognosis in their functional status, health-related quality
of life, hospitalization frequency and mortality. Several
generic indices have been proposed to weight specific
comorbidities based on the strength of their association
with outcome, in order to more accurately predict the as-
sociation of overall comorbidity and adverse outcomes.
One of the most widely used comorbidity indices, the
CCI was derived to predict 1-year mortality in hospitalized
patients [8], but has been widely applied and validated
outside of this setting [10]. In RA, the CCI has been
used to measure the association between comorbidity
and disability [11]. Given the significant adverse effects
of comorbidities in RA and their association with poor
prognosis, the disease-specific RDCI has been derived
in an RA population for better estimation of outcome [9].
Methods
Data sources and cohort
The Royal College of General Practitioners (RCGP)
Research and Surveillance Centre (RSC) database was
used for this study. It comprises the pseudonymized pri-
mary care records of all individuals registered with a large
network of general practices, and provides a broadly rep-
resentative sample of the English primary care population
[12]. At the time of data extraction for this study, data were
available from 164 general practitioner (GP) practices
across England with a total population of 1 475 762
people. The RCGP RSC contains information on clinical
diagnoses, anthropometric measurements (e.g. body
mass index), laboratory tests [e.g. C-reactive protein
(CRP)] and prescriptions coded with the Read clinical
coding systems (a thesaurus of clinical terms) [13].
Coded data are inputted by clinicians and support staff
in primary care, uploaded directly from laboratories, or
automatically generated by the primary care system (e.g.
when entering anthropometric measurements or generat-
ing patient prescriptions). Diagnoses arising in secondary
care are uploaded to the primary care record following
receipt of the record of the secondary care interaction,
which is almost universally sent to the patient’s registered
general practitioner. UK general practice lends itself to
this type of study because it is a registration-based
system (each patient registers with a single general
practitioner) [14, 15]; it has been computerized since the
1990s, with laboratory links and pay-for-performance
from 2004 that has resulted in consistent data entry
about chronic disease. Studies and outcomes based on
RCGP RSC data have been published across a range of
chronic diseases [1618].
Inclusion criteria specified individuals aged 18 years
and older with a confirmed diagnosis of RA prior to 1
January 2017. RA was identified using a validated algo-
rithm (sensitivity 84% and specificity 86% for RA) [19] de-
veloped using UK primary care data that has more
recently been updated to incorporate recent treatment
and clinical codes [20]. We reviewed these code lists
and added further medication codes for newer DMARDs
that had not previously been available. The study start
date was the date of diagnosis for individuals with RA,
indicated by first diagnostic code. Individuals with RA
were age- and sex-matched at general practice level
with individuals without either RA or a diagnosis of psori-
atic arthritis, ankylosing spondylitis, other spondyloarthro-
pathy or connective tissue disease. This latter cohort was
used to form a control population. Matching was per-
formed using a 1: 1 ratio. A subset of individuals with at
least 3 years’ follow-up after the study start date was also
defined, to examine whether incident comorbidities were
more common in individuals with RA than in the control
group. The follow-up period extended to the study end:
either 1 January 2017 or the date of patient transfer from
an included practice, or death. We report patient smoking
status using the most recently recorded smoking status in
the GP record prior to the index date. We report ethnicity
identified from ethnicity codes recorded in the patient
record using an approach previously reported [21].
Study approval was granted by the Research
Committee of the RCGP RSC. The study did not meet
the requirements for formal ethics board review as defined
using the NHS Health Research Authority research deci-
sion tool (http://www.hra-decisiontools.org.uk/research/).
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Comorbidity measures
Comorbidity variables were selected based on their
inclusion in either the RDCI or CCI comorbidity index.
The CCI comprises 19 conditions: myocardial infarction,
congestive cardiac failure, peripheral artery disease,
cerebrovascular disease, dementia, chronic pulmonary
disease, rheumatic or connective tissue disease, peptic
ulcer disease, mild and moderatesevere liver disease,
diabetes with and without complications, hemiplegia,
renal disease, solid tumours with and without metastatic
disease, leukaemia, lymphoma, and AIDS [8]. In the
CCI each condition is assigned a score of 1, 2, 3, or 6.
The RDCI comprises lung disease, heart attack, stroke,
other cardiovascular disease, hypertension, fracture,
depression, diabetes, cancer, and peptic ulcer or stom-
ach problems. The RDCI assigns a score of 1 or 2 to each
condition although heart attack, stroke, other cardiovas-
cular disease and hypertension can only score a max-
imum of 2 points in total; the score ranges from 0 to 9
[9]. Three chronic lung diseases were also evaluated
separately: asthma, chronic obstructive pulmonary dis-
ease (COPD) and interstitial lung disease (ILD).
Mortality and joint destruction outcome measures
We analysed the association of comorbidity burden and
mortality using the time to all-cause mortality as the outcome
in regression models. Time to incident joint surgery was used
as a surrogate measure of joint damage in separate regres-
sion models. Joint surgery was defined as any joint proced-
ure including arthroplasty, arthrodesis, synovectomy,
osteotomy and arthroscopy. Joint surgeries were classified
as shoulder, elbow, hip, knee and distal joint (wrist, ankle,
hand and foot) operations. Two joint surgery outcome defin-
itions were evaluated: a composite of any joint surgery
(excluding joints not listed above such as the spine) and a
composite of medium and small joint surgery—shoulder,
elbow and distal joints. The rationale for using incident joint
surgery as a surrogate marker for joint destruction was a
pragmatic decision as it was the only available measure of
joint damage that would have been accurately recoded in the
primary care record. Within the record there was a lack of
routinely collected data on a validated disease activity mea-
sure, such as the Disease Activity Score in 28 joints (DAS28)
[22] or radiographic joint damage.
Statistical analysis
We evaluated differences in baseline characteristics, includ-
ing prevalent comorbidities, between those with and without
RA using the 2 test for categorical variables and the un-
paired t test for continuous data. All reported P-values are
two-sided. We also compared the incidence of new (first-
ever) comorbidities within the first 3 years post-diagnosis
across the cohorts. Those with complete data for the first
3 years after the index date were eligible for inclusion in this
latter analysis, i.e. those who remained registered through-
out the follow-up period and did not die during follow-up.
We also report the incidence rates of the same comorbid-
ities in the complete cohort over the first 3 years post-diag-
nosis including those with a shorter duration of follow-up.
We calculated event rates for all-cause mortality and
first joint surgery as the number of events divided by the
total person-years of follow-up and expressed as the
number per 1000 person-years. The association between
comorbidity burden, as reflected separately by the two
comorbidity indices (CCI and RDCI), and the primary
and secondary outcomes was evaluated in both un-
adjusted analyses and in age and gender adjusted Cox
proportional hazard models. As a measure of model per-
formance, the discrimination ability of each comorbidity
index was estimated using Harrell’s C-index. The associ-
ation of each individual chronic lung disease (COPD,
asthma and ILD) with the same outcomes was evaluated
using Cox proportional hazard models adjusted for
comorbidity index (with respiratory components of the
indices removed), age and gender.
Whilst conducting the analysis described above we
found substantial differences in the prevalence of lung
diseases in those with RA at diagnosis compared with
those without. Therefore, we performed a post hoc ana-
lysis to assess by how long these conditions predated
the diagnosis of RA. We report the median time from
diagnosis of lung disease (asthma, COPD and ILD) to
RA diagnosis with interquartile range (IQR) and the pro-
portion diagnosed in the 2 years preceding RA diagnosis.
An equivalent analysis was performed for those control
patients with these lung diseases. All statistical analyses
were performed in R statistical package software version
3.2.1 (R Foundation for Statistical Computing, Vienna,
Austria).
Results
There is an excess of common comorbidities,
including respiratory conditions, at RA diagnosis
From the RCGP RSC database, 6591 incident cases of RA
were identified, and matched with 6591 controls without
RA. The mean age was 59.8 years and 32.5% were male.
Individuals with RA were more likely to be of white
ethnicity compared with controls. Smoking was more
prevalent in people with RA. Several comorbidities were
more common among patients with RA when compared
with controls: stroke, hemiplegia, chronic lung disease,
diabetes, previous fracture, liver disease, peptic ulcer dis-
ease and depression (Table 1). Mean comorbidity scores
were significantly greater among patients with RA com-
pared with those without when measured by CCI and
RDCI, and this difference persisted after excluding ‘con-
nective tissue disease’ from the CCI calculation (Table 2).
All respiratory conditions evaluated (COPD, asthma,
interstitial lung disease) were more common in individuals
with RA than in the control population.
There is an excess of incident comorbidities after the
diagnosis of RA
The majority of people in both cohorts had complete
follow-up for 3 years after the index date: 4646 (70.5%)
cases and 4667 (70.8%) controls (P = 0.688). There was
a greater incidence of several comorbidities within 3 years
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TABLE 1 Presence of comorbidities among individuals with and without RA, at diagnosis and after 3 years
RA at diagnosis
(n=6591)
Controlsa
(n=6591) P-value
RA at
3 years
(n=4646)
Controlsa at
3 years
(n=4667) P-value
Age, years 59.8 (15.8) 59.8 (15.8) 1.000 64.1 (15.5) 64.4 (15.7) 0.445
Male sex 2142 (32.5) 2142 (32.5) 1.000 1475 (31.7) 1468 (31.5) 0.778
Ethnicity 0.026 0.004
White 4883 (91.6) 4428 (92.8) 3451 (91.8) 3136 (93.3)
Asian 255 (4.8) 174 (3.6) 181 (4.8) 118 (3.5)
Black 128 (2.4) 125 (2.6) 79 (2.1) 84 (2.5)
Mixed 26 (0.5) 24 (0.5) 22 (0.6) 11 (0.3)
Other 36 (0.7) 21 (0.4) 25 (0.7) 11 (0.3)
Smoking status <0.001 <0.001
Active smoker 1499 (23.0) 1231 (18.9) 812 (17.5) 725 (15.7)
Ex-smoker 3090 (47.4) 2968 (45.6) 2560 (55.2) 2410 (52.1)
Never smoked 1926 (29.6) 2307 (35.5) 1265 (27.3) 1492 (32.2)
Myocardial infarction 202 (3.1) 182 (2.8) 0.325 37 (0.8) 29 (0.6) 0.377
Heart failure 108 (1.6) 89 (1.4) 0.196 45 (1.0) 27 (0.6) 0.042
Hypertension 2063 (31.3) 1964 (29.8) 0.064 278 (6.0) 229 (4.9) 0.025
Peripheral artery disease 103 (1.6) 78 (1.2) 0.072 23 (0.5) 15 (0.3) 0.249
Stroke or TIA 254 (3.9) 209 (3.2) 0.037 60 (1.3) 45 (1.0) 0.162
Hemiplegia 26 (0.4) 11 (0.2) 0.021 5 (0.1) 3 (0.1) 0.719
Other cardiovascular disease 600 (9.1) 509 (7.7) 0.005 125 (2.7) 86 (1.8) 0.007
Chronic lung disease 1390 (21.1) 1033 (15.7) <0.001 158 (3.4) 86 (1.8) <0.001
COPD 466 (7.1) 255 (3.9) <0.001 123 (2.6) 75 (1.6) 0.001
Asthma 1118 (17.0) 891 (13.5) <0.001 49 (1.1) 40 (0.9) 0.382
Interstitial lung disease 52 (0.8) 3 (0.0) <0.001 40 (0.9) 4 (0.1) <0.001
Diabetes 660 (10.0) 542 (8.2) <0.001 81 (1.7) 61 (1.3) 0.102
Diabetes with no end-organ damage 217 (3.3) 136 (2.1) <0.001 28 (0.6) 30 (0.6) 0.909
Diabetes with end-organ damage 443 (6.7) 406 (6.2) 0.201 133 (2.9) 82 (1.8) <0.001
Fracture 1609 (24.4) 1465 (22.2) 0.003 146 (3.1) 129 (2.8) 0.309
Malignancy without metastases 366 (5.6) 342 (5.2) 0.374 34 (0.7) 32 (0.7) 0.806
Malignancy with metastases 6 (0.1) 7 (0.1) 1.000 7 (0.2) 2 (0.0) 0.180
Mild liver disease 138 (2.1) 92 (1.4) 0.003 38 (0.8) 22 (0.5) 0.050
Moderate-severe liver disease 13 (0.2) 2 (0.0) 0.010 2 (0.0) 0 (0.0) 0.477
Peptic ulcer disease 250 (3.8) 199 (3.0) 0.021 41 (0.9) 12 (0.3) <0.001
Rheumatic or connective
tissue diseasea
6591 (100.0) 0 (0.0) NA NA NA NA
Dementia 33 (0.5) 33 (0.5) 1.000 44 (0.9) 22 (0.5) 0.009
Depression 1855 (28.1) 1519 (23.0) <0.001 235 (5.1) 124 (2.7) <0.001
Data are mean (S.D.) or n (%). P-values from 2 test or t test are provided. The following variables had missing values: ethnicity
in RA at diagnosis, n= 1263; no RA, n= 1921; RA at 3 years, n= 888; no RA at 3 years, n= 1307; smoking status in RA at
diagnosis, n= 76; no RA, n= 85; RA at 3 years, n= 9; no RA at 3 years, n= 40. aPeople with RA, psoriatic arthritis, ankylosing
spondylitis, other spondyloarthropathies or connective tissue disease, e.g. systemic lupus erythematosus, are excluded from
the controls by definition. Non-RA connective tissue disease were also excluded from the cases by definition. NA: not
applicable; TIA: transient ischaemic attack.
TABLE 2 Mean scores for comorbidity indices among patients with RA at diagnosis and age- and sex-matched controls
RA (n=6591) Controla (n=6591) P-value
RDCI, mean (S.D.) 1.63 (1.48) 1.38 (1.37) <0.001
CCI, mean (S.D.) 1.68 (1.06) 0.55 (0.97) <0.001
CCI excluding connective tissue diseasea, mean (S.D.) 0.68 (1.06) 0.55 (0.97) <0.001
aPeople with RA, psoriatic arthritis, ankylosing spondylitis, other spondyloarthropathies or connective tissue disease, e.g.
systemic lupus erythematosus, are excluded from the controls by definition. Non-RA connective tissue diseases were also
excluded from the cases by definition. CCI: Charlson Comorbidity Index; RDCI: Rheumatic Disease Comorbidity Index.
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of diagnosis in RA patients compared with controls
(Table 1 and Supplementary Table S1, available at
Rheumatology online), including heart failure, hyperten-
sion, peptic ulcer disease and depression. Incident diag-
noses of COPD and ILD were also substantially more
common within the first 3 years in RA patients. There
was no difference in incident asthma diagnoses.
Greater comorbidity is associated with mortality but
not joint surgery
A total follow-up duration of 36 745 person-years was
available for people with RA: a mean (S.D.) follow-up of
5.58 (3.59) years per patient. The proportion of patients
who had some form of joint surgery in the 3 years follow-
ing RA diagnosis was 10.4% (Table 3). Cumulative rates of
all-cause mortality were greater with higher RDCI and CCI
scores, although separation of the cumulative incidence
curves was less marked for the CCI score (Figs 1 and 2).
In unadjusted analyses, higher CCI and RDCI scores
were both significantly associated with an increased risk
TABLE 3 Event rates for joint surgery outcomes among
patients with RA
RA (n=6591)
Outcome No events
Events per
1000 person-years
(95% CI)
Shoulder operations 49 (0.7) 1.34 (0.991.77)
Elbow operations 14 (0.2) 0.38 (0.210.64)
Hip operations 236 (3.6) 6.54 (5.737.44)
Knee operations 371 (5.6) 10.40 (9.3611.52)
Distal jointa operations 94 (1.4) 2.59 (2.093.17)
Medium or small
jointb operations
155 (2.4) 4.29 (3.655.03)
Any jointc operation 686 (10.4) 20.11 (18.6321.69)
aDistal joints comprise wrist, ankle, hand and foot joints.
bMedium and small joints comprise shoulder, elbow and
distal joints. cAny joint includes all joints listed in the table;
spinal and other joints not listed are excluded.
FIG. 1 Cumulative all-cause mortality according to RDCI score among patients at diagnosis of RA
RDCI: Rheumatic Disease Comorbidity Index.
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of all-cause mortality, and risk was similar for both indices
in adjusted analyses (Table 4). Higher RDCI but not CCI
scores were associated with an increased risk of any joint
surgery in unadjusted but not adjusted analysis. Model
performance was similar for both the RDCI and CCI
score models (Table 4). There was no evidence of an as-
sociation between either index and risk of medium and
small joint surgery.
COPD is an important predictor of all-cause mortality
in RA
COPD was associated with a near 3-fold increase
in the risk of mortality [hazard ratio (HR) 2.84, 95% CI
1.137.12; P = 0.027], whereas there was no evidence
of an association for asthma (HR 1.79, 95% CI
0.754.30; P = 0.192). Numbers of individuals with ILD
were insufficient to assess the association between ILD
and risk of mortality.
Where interstitial lung disease predates RA diagnosis
it usually occurs in the preceding few years
Almost half of ILD cases (23 of 52; 44%) were diagnosed
within the 2 years preceding the diagnosis of RA, and a
first diagnostic code for ILD predated RA by a median of
2.2 (IQR 0.66.3) years. The three cases of ILD in controls
predated the matched index date by a median of
10.2 years (P = 0.032 for comparison vs cases). Where
COPD preceded a diagnosis of RA, only 25.8% (120 of
466) occurred in the preceding 2 years, with COPD pre-
ceding RA by a median of 4.5 (IQR 1.98.2) years. COPD
preceded the index date in controls by a median of 5.1
(IQR 1.98.6) years (P = 0.407 for comparison vs cases).
Just 7.0% (78 of 1118) of asthma cases that preceded RA
occurred in the 2 years before diagnosis, with asthma pre-
ceding RA by a median of 12.5 (IQR 6.920.7) years.
Asthma preceded the index date in controls by a
median of 13.2 (IQR 7.420.4) years (P = 0.471 for com-
parison vs cases).
FIG. 2 Cumulative all-cause mortality according to CCI score among patients at diagnosis of RA
CCI: Charlson Comorbidity Index.
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Discussion
We found that people with RA have a substantially higher
burden of comorbidity at diagnosis compared with
matched individuals without RA. The incidences of several
comorbidities, including heart failure, peptic ulcer disease,
depression, COPD and ILD, were also greater in the first
3 years after diagnosis than in controls. Our study shows
that even in early RA, both the RDCI and CCI comorbidity
indices were associated with an increased risk of all-
cause mortality. Age and gender adjusted models using
both these scores had good discriminative ability to pre-
dict mortality. However, neither index was associated with
risk of disease progression, as measured by the need for
joint surgery as a surrogate marker of joint destruction.
Respiratory diseases (COPD, asthma and ILD) were all
more common at diagnosis than in controls. COPD at
diagnosis, but not asthma, was associated with a near
3-fold increased risk of early mortality. The sample size
for ILD was insufficient to assess for any association.
The prevalence of comorbidity, including cardiovascular
and respiratory disease, has previously been reported to
be higher in individuals with RA at diagnosis than in the
general population [23] and has been increasing over time
[24]. In contrast, Swedish casecontrol studies have
observed that although cardiovascular risk increases rap-
idly following RA diagnosis [25], there is no evidence of an
increase in ischaemic heart disease prior to the onset of
RA [26]. However, an important limitation of this previous
comparative work is that methods of assessment of
comorbidity were different in cases and controls; cases
were recruited to the study, with assessment of comor-
bidity via patient self-reporting, clinical assessment and
medical records review, whereas population controls
and their comorbidities were identified using electronic
health records. We were able to corroborate these find-
ings in our study, which has the strength of applying the
same approach to assess comorbidity in both individuals
with and those without RA. Our matched analysis also
benefits from identifying controls from the same GP prac-
tice as cases. Our data also support analyses using the
Finnish nationwide disease register, which suggested
elevated cardiovascular risk precedes the clinical onset
of RA [27]. Several studies have also demonstrated that
RA-associated lung disease can precede the onset of clin-
ically significant RA [28], but to our knowledge the dur-
ation between lung disease onset and RA diagnosis has
not previously been explored in a community-based
cohort. The differences in temporal association between
COPD, asthma and RA most likely reflect the differences
in age of onset of these conditions. However, it is inter-
esting to observe that where ILD does predate RA it usu-
ally occurs within the few years immediately before RA
diagnosis.
COPD is associated with a 3-fold increase in mortality in
the general population and asthma with a very small
increased mortality risk in adults [29]. These results are
consistent with our findings in those with RA; we cannot
exclude the possibility of a small association between
asthma and mortality given our sample size. Given the
high overall mortality in people with RA the additional 3-
fold risk conferred by the presence of COPD is of particu-
lar importance in this group. This contrasts, for example,
with the situation in patients with heart failure, where the
presence of COPD confers only a small additional mortal-
ity risk (HR 1.19; 95% CI 1.021.39) [30].
The excess burden of COPD and perhaps cardiovascu-
lar disease in people with RA at diagnosis may be, at least
in part, related to the greater incidence of smoking we
observed in people with RA. Multiple previous studies
have found that smoking is a risk factor for the develop-
ment of RA, which is consistent with our results [31]. This
underscores the importance of smoking cessation advice
and support as part of the routine management of people
with and at risk of RA. A holistic and patient-centric ap-
proach to the care of people with RA is vital.
Our study corroborates the findings of England and col-
leagues who compared the RDCI with other comorbidity
indices for predicting disease outcomes; in their study, the
RCDI performed well as a predictor of mortality [32]. We
find this holds true in early RA. To our knowledge, no other
studies have assessed whether the RDCI is associated
with the need for joint surgery.
TABLE 4 Hazard ratio for the association between comorbidity index as assessed at diagnosis and outcome in RA
All-cause
mortality
Model
C-statistic
Any joint
surgery
Model
C-statistic
Medium or small
joint surgery
Model
C-statistic
CCI unadjusted
HR (95% CI; P-value)
1.53 (1.211.93;
P < 0.001)
0.650 1.01 (0.941.09;
P = 0.764)
0.502 0.84 (0.691.02; P = 0.073) 0.541
CCI adjusteda
HR (95% CI; P-value)
1.30 (0.991.70;
P = 0.057)
0.814 0.94 (0.871.01;
P = 0.101)
0.600 0.83 (0.681.01; P = 0.068) 0.582
RDCI unadjusted
HR (95% CI)
1.50 (1.201.87;
P < 0.001)
0.682 1.08 (1.031.14;
P = 0.002)
0.542 0.96 (0.861.08; P = 0.500) 0.505
RDCI adjusteda
HR (95% CI)
1.26 (1.001.59;
P = 0.049)
0.815 1.03 (0.971.08;
P = 0.334)
0.600 0.96 (0.851.08; P = 0.461) 0.568
aAdjusted for age and gender. CCI: Charlson Comorbidity Index; HR: hazard ratio; RDCI: Rheumatic Disease Comorbidity
Index.
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This study benefits from the large sample size and the
ability to use data routinely collected prior to a diagnosis
of RA to assess baseline comorbidities. UK primary care
provides a high level of data quality in the recording and
monitoring of chronic disease and the quality of data
within the RCGP RSC network is high in this regard [12,
33, 34].
There are several limitations to the present study.
Although the cohort is derived from a nationally represen-
tative sample of England [12], the results may not be gen-
eralizable to other populations. The possibility of residual
confounding cannot be excluded in any observational
study of this type. In common with other studies using
routinely collected data, our study relies on accurate re-
cording of disease by clinicians at participating practices.
This limitation was mitigated against by using a recom-
mended approach for variable definition, defining compre-
hensive code lists to maximize correct disease
identification [13, 35]. No secondary care data linkage
was used for this study and therefore we rely on primary
care recording of events; this may have led to some
underestimation of comorbidities. Our analyses were
also limited by the lack of data on cause-specific mortal-
ity. Joint surgery type is often recorded using high-level
Read codes in primary care, i.e. the specific procedure is
not recorded just the joint operated upon. We were there-
fore unable to restrict our analysis to joint replacement
surgery and relied on joint surgery as a surrogate marker
for joint damage. In our analysis of the prevalence of
comorbidity between cases and controls 3 years after
diagnosis, we cannot exclude the possibility of under-
identification of conditions in the control group due to
reduced surveillance. There is also a possible survival
bias in this assessment of incident comorbidities at
3 years as continuous registration was an a priori require-
ment for this subset; we therefore may have slightly
underestimated the incident comorbidity burden in both
cases and controls.
Implications of our findings
With increasing life-expectancy and improved control of
joint disease in RA the relative importance of comorbidity
in RA is increasing [36]. However, globally the quality of
evaluation, monitoring and treatment of comorbidities in
RA is variable with considerable scope for improvement
[37]. Our findings highlight the importance of assessing
comorbidity in individuals with newly diagnosed RA, in
line with existing literature [24, 38, 39]. In particular, we
found individuals with RA were more likely to have existing
cardiovascular disease, respiratory disease and depres-
sion. We also found, incident comorbidities were much
more common in the years subsequent to a diagnosis of
RA compared with matched individuals without RA, sug-
gesting a need for clinicians to reassess comorbidity fre-
quently post-diagnosis in the RA population, especially as
medications used for RA treatment are associated with
several comorbidities. Early identification of these comor-
bidities should enable early intervention to minimize future
morbidity and mortality and to help avoid RA treatments
that may worsen some comorbidities. Future research
should explore the impact of this early intervention.
Further research is also needed to explore whether the
excess burden of comorbidities at diagnosis of RA
varies between those who are seropositive and those
who are seronegative. Our findings also provide good
ground for the future development of a tool to calculate
individual mortality risk in RA using comorbidity burden,
for use in routine clinical practice.
Conclusions
There is an excess burden of comorbidity around the time
of diagnosis of RA, including increased respiratory dis-
ease (COPD, asthma and ILD). Both the CCI and RDCI
comorbidity indices predict risk of all-cause mortality in
early RA but not joint surgery. We also found that the
presence of COPD was a major predictor of early mortality
in RA. Individuals with RA also appear to accumulate
many comorbidities more rapidly than controls in the
first few years after diagnosis. Early and repeated assess-
ment of comorbidities, including respiratory disease,
should form part of the routine care of RA patients.
Management of comorbidities, especially preventable
and modifiable ones and associated risk factors, early
on in the disease course, may improve outcomes and
quality of life.
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